Compare American Tower Corp (AMT) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Bristol-Myers Squibb Co — how do they compare? American Tower Corp trades at $169.8 (market cap $79.00B), while Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and American Tower Corp pays the higher dividend (4.12%). Which is the better fit depends on your goals.
| AMT | BMY | |
|---|---|---|
Market Cap | $79.00B | $129.94B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $65.89 |
52-Week Low | $162.11 | $42.60 |
Enterprise Value | $122.53B | $163.92B |
Dividend Yield | 4.12% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower Corporation (AMT) trades at $170.48, up 0.81% with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals despite analyst optimism, with 79.6% buy ratings and a $206.17 consensus price target representing 21% upside potential. Recent Q2 2026 results demonstrated accelerated lease contract growth and raised full-year guidance.
AMT presents a compelling investment case with strong revenue visibility from telecom infrastructure demand and 5G/6G expansion cycles. However, high debt levels and interest rate sensitivity pose significant risks. The stock offers defensive characteristics through recurring revenue streams but faces headwinds from DISH Network churn and capital expenditure requirements.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
